GLP-1 agonists

Incretins and Questions About the Pancreas

 
Over the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.
 
At that conference Dr.